New data confirms superiority of docetaxel based triplet therapy in gastric cancer

(European Society for Medical Oncology) The superiority of docetaxel based triplet therapy over standard care in patients with resectable esophago-gastric cancer has been confirmed in late-breaking results from the FLOT4 trial presented at the ESMO 2017 Congress in Madrid.